These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34391596)
1. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Núñez López C; González de Abreu JM; Pérez-Blanco V; de Miguel Buckley R; Romero Gómez MP; Díaz-Menéndez M; ; Enferm Infecc Microbiol Clin (Engl Ed); 2021 Jul; ():. PubMed ID: 34391596 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Núñez López C; González de Abreu JM; Pérez-Blanco V; de Miguel Buckley R; Romero Gómez MP; Díaz-Menéndez M; ; Enferm Infecc Microbiol Clin (Engl Ed); 2023 Jan; 41(1):33-35. PubMed ID: 36621246 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Núñez López C; González de Abreu JM; Pérez-Blanco V; de Miguel Buckley R; Romero Gómez MP; Díaz-Menéndez M; ; Enferm Infecc Microbiol Clin; 2023 Jan; 41(1):33-35. PubMed ID: 34334860 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study. Guijarro C; Galán I; Martínez-Ponce D; Pérez-Fernández E; Goyanes MJ; Castilla V; Velasco M Clin Microbiol Infect; 2021 Nov; 27(11):1699.e1-1699.e4. PubMed ID: 34197936 [TBL] [Abstract][Full Text] [Related]
5. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048 [TBL] [Abstract][Full Text] [Related]
6. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
7. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
9. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. Bouton TC; Lodi S; Turcinovic J; Weber SE; Quinn E; Korn C; Steiner J; Schechter-Perkins EM; Duffy E; Ragan EJ; Taylor BP; Schaeffer B; Miller N; Davidoff R; Hanage WP; Connor J; Pierre C; Jacobson KR medRxiv; 2021 Apr; ():. PubMed ID: 33821283 [TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients. Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894 [TBL] [Abstract][Full Text] [Related]
12. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069 [TBL] [Abstract][Full Text] [Related]
13. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
14. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark. Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115 [TBL] [Abstract][Full Text] [Related]
15. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain). Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J; Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393 [TBL] [Abstract][Full Text] [Related]
16. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Buonfrate D; Piubelli C; Gobbi F; Martini D; Bertoli G; Ursini T; Moro L; Ronzoni N; Angheben A; Rodari P; Cardellino C; Tamarozzi F; Tais S; Rizzi E; Degani M; Deiana M; Prato M; Silva R; Bisoffi Z Clin Microbiol Infect; 2021 Dec; 27(12):1845-1850. PubMed ID: 34329793 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
18. Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan. Kaneko H; Tsuboi H Brain Behav Immun; 2023 Jan; 107():414-418. PubMed ID: 36116693 [TBL] [Abstract][Full Text] [Related]
19. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Vicenti I; Basso M; Gatti F; Scaggiante R; Boccuto A; Zago D; Modolo E; Dragoni F; Parisi SG; Zazzi M Int J Infect Dis; 2021 Nov; 112():40-44. PubMed ID: 34481967 [TBL] [Abstract][Full Text] [Related]
20. [COVID-19 infections and effectiveness of the vaccination among healthcare workers]. Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]